AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$PTIX

ARMEN GARO H purchased $13K of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 20,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.65 on 2026-08-21.

Original reporting
SEC EDGAR · ARMEN GARO H
Published Aug 24, 2026, 5:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 5:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PTIX
Neutral
high confidence
Mentioned
$PTIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTIXNeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to influence market perception significantly.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the insider's timing more meaningful.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$PTIXNeutralHigh confidence
Context

Form 4 disclosed insider purchase of 20,000 shares at $0.65 each, total $13,000.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The transaction size is trivial relative to market cap; typical insider purchases of this magnitude rarely move the stock.

Market effects

Sector

None; the trade is company‑specific and does not affect the broader biotech sector.

Regional

None; the filing is U.S.‑based with no regional ripple.

Global

None; micro‑cap insider activity has no global market significance.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong confidence signal.

Key entities

  • Executive Chair & Principal Officer
    Armen Garo H

    Insider reporting a purchase of PTIX shares.

  • Biotech Company
    Protagenic Therapeutics, Inc.

    Issuer of the shares purchased.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTIX insider trading history →

Related articles

AUG 20
$PTIXMedAI 8/10

Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

Protagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.

finanznachrichten.de2 min
JUL 31
$PTIXMed

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY

^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

onvista.de4 min